Inhalation Science

Breathing Simulation Testing

Simulate realistic breathing profiles to quantify inhaled and respirable dose, emissions, and interface effects during device use.

Programmable breathing simulators use adult and pediatric mouth/nose fixtures. Dose is collected with cascade impactors or filters and quantified by HPLC, ELISA, or ddPCR, depending on the study.

ISO 17025USP <601>USP <1601>FDA MDI / DPI / nasalReviewed 2026-10-20
Request a quoteSubmit a sample

Purpose & when to use

Breathing Simulation Testing uses a programmable pump to replicate human inhalation profiles, including tidal volume, flow rate, and breath duration. We quantify inhaled and respirable dose delivered through the device interface. Compendial configurations align to USP <601> and USP <1601>. Adult and pediatric profiles are programmable, with ISO 27427 and FDA MDI / DPI / nasal guidance informing study design. Breathing simulation is used for:

  1. Inhaled dose comparisons across MDIs, DPIs, nebulizers, and soft-mist inhalers — profile-resolved dose datasets aligned to USP <601> and FDA MDI / DPI / nasal guidance for submission and change-control packages.
  2. Pediatric-to-adult profile mapping for inhalation and intranasal products — bracketing use-condition variability across age-scaled tidal volumes and flow rates under FDA pediatric-study guidance.
  3. Mask and valved holding chamber (VHC) interface-effect studies — quantifying leakage, dead-space, and coordination impacts under ISO 27427 nebulizing-equipment and FDA MDI / DPI guidance framing.
  4. Respirable-fraction estimation by pairing breathing simulation with cascade impactor PSD — links device emissions to predicted lung deposition under USP <601> aerodynamic-size framing.
  5. Sensitivity and profile-variability mapping across breathing conditions, actuation timing, and device orientation — supports ICH Q9 risk-assessment and FDA change-control packages.

Use breathing simulation when you need inhaled-dose data tied to realistic use conditions: pediatric or adult profiles, interface variability, or comparisons across devices. The dataset can support an engineering decision, a regulatory submission, or a risk-assessment package.

Built for inhalation and intranasal drug delivery devices

Breathing simulation characterises performance across the device classes where realistic use conditions — patient breathing pattern, interface geometry, and actuation timing — drive the dose the patient receives.

  • MDIMetered-dose inhalers
  • DPIDry-powder inhalers
  • NebulizerLiquid aerosol generators
  • Nasal sprayIntranasal pump delivery
  • Spacer / VHCValved holding chambers

Instrumentation & measurement ranges

We select the platform based on the device class, breathing profile, and regulatory framework. Components are confirmed during study planning and recorded in the method report.

5 – 100 L/mininhalation-flow

Programmable breathing simulator (ASL 5000 or equivalent)

Piston-driven breathing pump with programmable tidal volume, flow rate, and breath duration — adult and pediatric profiles selectable; profile fidelity verified against the set waveform before each campaign.

0.1 – 5 sinhalation-duration

Adult and pediatric mouth/nose fixtures and headforms

USP-geometry induction ports, adult/pediatric nose-throat models, and headform-style interfaces — geometry matched to the device class and the patient population under study.

0.4 – 11 µmaerodynamic

Cascade impactors and filter-based collection (NGI / Andersen)

Downstream dose collection via NGI or Andersen cascade impactor stages, or a validated filter assembly — collection method selected to match the size-fraction and dose endpoint required.

0.1 – 1000 µgper-profile

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix, with system suitability and recovery documented per assay.

Test method options

MethodStrengthsTradeoffAligned with
Compendial-aligned breathing simulation (USP <601> / <1601>)
  • Submission-grade inhaled-dose datasets under defined fixtures and breathing profiles — the canonical USP <601> and USP <1601> compendial package for inhalation characterisation.
  • Documented acceptance logic and statistical framing for FDA MDI / DPI / nasal submissions, lifecycle changes, and predicate comparisons.
Strict configuration control and documentation overhead — best when device and formulation are locked enough to justify the filing-bound setup cost.
USP <601>USP <1601>FDA MDI / DPI / nasal
Interface and mask effects study (fixture sweep)
  • Directly measures mask, spacer, and VHC leakage effects on inhaled dose — answers the interface-sensitivity question FDA MDI / DPI guidance requires.
  • Controlled fixture protocol surfaces dose differences attributable to interface geometry alone, isolating interface impact from device variability.
Careful fixture fabrication and leak-check protocol needed to avoid measurement artifacts that obscure real interface effects.
FDA MDI / DPI / nasalISO 27427
User-variability mapping (breathing profile sweep)
  • Brackets realistic breathing-pattern variability from pediatric low-flow to adult high-flow profiles — supports ICH Q9 risk-assessment and FDA change-control packages.
  • Profile-resolved dose dataset directly informs device-label guidance (optimal flow rate, coordination requirements) and user-group selection rationale.
More profiles increase replicate count and study duration — scope tightly to the profile range that drives the specific decision.
ICH Q9FDA MDI / DPI / nasal
Emissions-to-exposure translation (fit for purpose)
  • Links device emissions to breathing-zone inhaled dose under defined scenarios — supports exposure assessment beyond the compendial collection endpoint.
  • Pairs with emitted-dose data to build a full dose-to-patient picture; framing aligned to FDA CMC guidance for consumer and medical devices.
Requires explicit scenario definition and documented assumptions — results are scenario-specific and must be scoped carefully to avoid over-generalisation.
FDA MDI / DPI / nasal

Setup configurations

We configure each breathing simulation study for the device, patient population, and regulatory framework. The setup needs to reproduce the specified tidal volume, flow rate, and breath duration while accounting for the practical constraints of the collection train and quantitation method. During study planning, we confirm the configuration choices below:

Device interfaces

Mouthpiece adapters, USP induction ports, adult/pediatric nose-throat models, and headform interfaces — geometry matched to the device class and the target patient population.

Flow & actuation profiles

Programmable tidal volume, peak flow rate, and inhalation duration — adult and pediatric waveforms logged against the set profile before each campaign with actuation timing synchronised to breath phase.

Sample numbers

Replicates per device and per profile — power sized to declared within-profile and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection (filter or impactor stages), extraction-solvent compatibility, and documented storage and chain of custody for collected fractions.

Environmental controls

Temperature and humidity conditioning when formulation or device performance is known to be sensitive — equilibration and environmental monitoring logged alongside dose collection.

Compliance frame for inhalation breathing simulation

Each breathing simulation study follows a documented quality system. The pharmacopoeial and regulatory references below guide study controls, records, and reporting for inhalation and intranasal products.

  • ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
  • USP <601>AccreditedInhalation and nasal drug products — performance quality tests with breathing-simulation provisions.
  • USP <1601>AlignedProducts for nebulization — characterization tests including breathing-simulator methods.
  • FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus breathing-pattern testing for inhalation submissions.

Key data outputs & reporting

Each breathing simulation study delivers inhaled-dose results by profile and condition, repeatability statistics, and the underlying datasets for submission packages, change-control documentation, or engineering decisions. The report presents interface-sensitivity comparisons and places the dose data in the context of the respirable fraction. Profile verification logs, fixture leak checks, and assay calibration records document traceable QA / QC controls throughout the study and accompany every report.

Primary outputs

  • Inhaled and respirable dose by breathing profile and condition — mean, SD, and CV across replicates, with profile-to-profile comparisons.
  • Interface sensitivity data — dose delta attributable to mask, spacer, or VHC geometry, with documented fixture-leak controls.
  • Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#FormatContents
01PDF reportMethods, breathing-profile setup, controls, statistical framing, and acceptance logic.
02CSV / XLSX datasetsPer-profile inhaled dose, replicate statistics, and condition deltas.
03FiguresDose-versus-profile plots, condition overlays, and interface-sensitivity charts for internal review and submission appendices.

QA / QC & data integrity

QA / QC controls are defined in the method plan for each breathing simulation study. The checks address profile fidelity, the collection train, and the analytical method, and run alongside dose collection. They are audited under our ISO 17025 quality system, with traceability from sample receipt through the final result.

Profile verification logs — breathing-simulator waveform confirmed against the set tidal volume, flow rate, and duration before each campaign and between condition blocks.

Fixture leak checks before and after each collection series — documented to bound leakage contribution to dose uncertainty.

Blanks and background controls for collection media, with stage and filter blanks run alongside device measurements.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes across HPLC, ELISA, and ddPCR endpoints.

Chain of custody from sample receipt through collection, extraction, quantitation, and final reporting.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

The answers below cover profile selection, pediatric testing, interface effects, quantitation, and deliverables for inhalation and intranasal product teams planning a breathing simulation study. If your device class, patient population, or regulatory framework differs from those described here, contact us to discuss the setup. Most studies involve at least one custom configuration decision that is easier to work through on a call.

Q.Can you run pediatric and adult breathing profiles in the same study?
A.Yes. We program adult and pediatric profiles within the same device test campaign and report dose metrics for each profile. The resulting age-bracketed dataset can support pediatric regulatory submissions.
Q.How do you measure inhaled dose from the breathing simulator?
A.We collect dose downstream of the mouth/nose interface using a filter or cascade impactor, then quantify it by HPLC, ELISA, or ddPCR matched to the active and matrix. Controls, blanks, and recovery are documented for each assay.
Q.Can you evaluate mask and spacer interface effects?
A.Yes. Mask and VHC effects are common study objectives. We systematically vary fixture configurations under controlled conditions, document leak checks, and report dose differences attributable to interface geometry rather than device variability.
Q.Is breathing simulation only for pharmaceutical products?
A.No. Breathing simulation also quantifies inhaled dose for consumer and medical devices where realistic breathing conditions affect exposure. We use the same simulator and collection methodology, with the study framed around the relevant regulatory or engineering decision.
Q.What do I receive at the end of the study?
A.You receive a PDF report documenting setup assumptions, profile logs, controls, and statistical framing; CSV / XLSX datasets with per-profile dose and replicate statistics; and figures showing dose versus profile and condition overlays.

Standards & guidance

ARE Labs aligns breathing simulation studies with pharmacopoeial, consensus, and regulatory standards for inhaler characterisation and inhalation product submissions. We document methods as accredited only where we hold third-party accreditation for the relevant scope (ISO 17025, USP <601>). When a standard is followed without formal accreditation, we describe the method as aligned or conformant where applicable. The cards below list the standards most often relevant to breathing simulation packages.

Inhalation & Drug Delivery - Accredited

USP <601>

Inhalation and nasal drug products — performance quality tests with breathing-simulation provisionsView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Products for nebulization — characterization tests including breathing-simulator methodsView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Chemistry, manufacturing, controls, and breathing-pattern testing for inhalation and intranasal submissionsView standard ->Inhalation & Drug Delivery - Aligned

ISO 27427

Anaesthetic and respiratory equipment — nebulizing systems and components using breathing simulatorsView standard ->QA & Regulatory - Aligned

ICH Q9

Quality risk management — risk-assessment and profile-variability framing for breathing simulation studiesView standard ->

Related services & devices

Service

Particle Size Distribution (PSD) Testing

Pairs with breathing simulation for inhalation submissions — stage-by-stage aerodynamic size data contextualises the respirable fraction of inhaled dose.Read more ->Service

Dose Uniformity & Emitted Dose Testing

Complement to breathing simulation — per-actuation emitted dose under controlled flow, providing the device-output baseline the simulator builds on.Read more ->Devices

Respiratory Drug Delivery Devices

MDI, DPI, and nebulizer programs — breathing simulation characterises real-world dose delivery across the inhalation device portfolio.Read more ->Devices

Intranasal Delivery Devices

Nasal pumps and unit-dose devices — breathing simulation with nose-throat models quantifies interface effects and realistic intranasal dose.Read more ->